Lovastatin for treating depression, a randomized double blind controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201304203930N22

Enrollment

Registered

2013-06-28

Start date

2013-04-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive disorder. Depressive episode

Interventions

Intervention 1: Fluoxetine (20-40mg/day) + Lovastatin (30mg/day) for 6 weeks. Intervention 2: Fluoxetine (20-40mg/day) +Placebo for 6 weeks.

Treatment - Drugs

Placebo

Fluoxetine (20-40mg/day) + Lovastatin (30mg/day) for 6 weeks

Fluoxetine (20-40mg/day) +Placebo for 6 weeks

Eligibility

Sex/Gender

All

Age

17 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: major depressive disorder according to DSM_VI, both gender, and aged between 17 and 70 years old. Exclusion criteria: receive NSAIDs concurrently, reported positive history of cancer, and hypothyroidism.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hamilton Derepssion Rating Scale. Timepoint: baseline, 2 week, and 6 week. Method of measurement: Interveiwe.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArvin Hedayati

Fasa University of Medical sciences

dr.arvinhedayati@gmail.com+98 71 1627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026